Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KIT V559X KIT N822I |
Therapy | Imatinib + Pembrolizumab |
Indication/Tumor Type | melanoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT V559X KIT N822I | melanoma | predicted - sensitive | Imatinib + Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, addition of Gleevec (imatinib) to Keytruda (pembrolizumab) in a patient with metastatic melanoma harboring an unspecified KIT V559 mutation and a KIT N822I resulted in a complete remission after 6 months and the patient stayed on therapy for 2 years (PMID: 31689840). | 31689840 |
PubMed Id | Reference Title | Details |
---|---|---|
(31689840) | Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report. | Full reference... |